I see this as a valuation reset rather than the end of the AI story. AI demand remains strong, but investors are becoming more selective about capital spending, financing costs and cash flow. Growth alone is no longer enough when valuations are stretched.
Personally, I would consider healthcare and consumer staples for diversification, as their earnings tend to be more resilient. However, I would not chase defensive stocks simply because they are outperforming. Valuation and cash flow still matter, especially in a higher-for-longer interest rate environment.
For my portfolio, I prefer to stay disciplined rather than react to short-term rotations. I will monitor Treasury yields, earnings and technical levels while continuing to accumulate quality companies patiently on pullbacks. Consistency over market noise remains my approach, and I believe patience is just as important as identifying the right opportunities.
@Tiger_comments @TigerStars @TigerClub
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments